Introduction
============

3,5-Di-*t*-butyl catechol (DTCAT) has been shown to release Ca^2+^from rat skeletal muscle sarcoplasmic reticulum (SR) vesicles, which makes it a possible candidate for use as a substitute for halothane or caffeine in the *in vitro*contracture test (IVCT) for the assessment of susceptibility to malignant hyperthermia (MHS).

Methods
=======

To characterize the effect of DTCAT at the cellular level, Ca^2+^release experiments were performed on cultured, human skeletal muscle cells using the fluorescent Ca^2+^indicator fura2-AM. DTCAT was also used for the first time in the IVCT to induce contractures in human skeletal muscle bundles obtained from individuals diagnosed susceptible (MHS), normal (MHN) or equivocal (MHE); these effects were compared to those elicited by the standard test substances caffeine and halothane.

Results
=======

In single cultured skeletal muscle cells, DTCAT released Ca^2+^from intracellular stores with a higher potency when compared to caffeine. This effect, however, was unspecific, since the release of Ca^2+^from stores other than the SR was evident, as well as a Ca^2+^influx, possibly triggered by depletion of intracellular Ca^2+^stores. DTCAT induced contractures in skeletal muscle bundles in a concentration-dependent manner with an EC~50~value of 160 ± 91 μM. However, the reaction to DTCAT in muscles from MHS individuals was similar to reactions to DTCAT in MHE or MHN muscles.

Conclusion
==========

Due to its low specificity in inducing the release of Ca^2+^from SR stores and the additional activation of Ca^2+^influx, DTCAT is not an appropriate test substance for the diagnosis of MH.
